Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left" rowspan="2">Test solution</td><td class="align_center" colspan="2">DARPin-associated activity (%)</td></tr><tr class="thead"><td class="align_center">1 h</td><td class="align_center">3 h</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">PBS</td><td class="align_center">99.7 ± 0.4</td><td class="align_center">97.9 ± 1.0</td></tr><tr><td class="align_left">1 M KI</td><td class="align_center">99.0 ± 0.3</td><td class="align_center">98.5 ± 0.4</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Stability of [<sup>125</sup>I]I-DARPin 9_29.</div>

Contrast Media & Molecular Imaging

tab1

Table 1

Table 1: Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors 

Table 1 | Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors 